The Batesville Area Chamber of Commerce had a ribbon-cutting ceremony for the opening of Beebe Hall at the Arkansas Sheriffs’ ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Share on Pinterest Wegovy resolved liver inflammation in nearly ... for these findings included 800 participants, who were mostly white adults evenly split between males and females, with an ...

Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...

Novo Nordisk's Wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449. Novo Nordisk ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, beginning this week. The company’s announcement comes as many compounding ...

But the power of the Hall of Fame is facing a unique test this year when the White Stripes enter since a reunion this November — even one where they don’t play a note of music together ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...